A biotech is proposing a plan to pay for its pricey rare disease treatment the same way you’d buy a TV or dishwasher. Here’s the inside story

Biotech Bluebird Bio proposed on Tuesday at a major healthcare conference a five-year installment plan for its pricey gene therapy. The company hasn’t put out a price tag for the experimental product, which hasn’t yet been approved in the US, but capped it at $2.1 million per treatment.   Bluebird CEO Nick Leschly told Business Insider the inside story of how the plan came about and what challenges it could face. 

Installment plans are used

Continue reading...